Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy

Frontiers in Immunology
Shih-Feng ChoYu-Tzu Tai

Abstract

The approval of the first two monoclonal antibodies targeting CD38 (daratumumab) and SLAMF7 (elotuzumab) in late 2015 for treating relapsed and refractory multiple myeloma (RRMM) was a critical advance for immunotherapies for multiple myeloma (MM). Importantly, the outcome of patients continues to improve with the incorporation of this new class of agents with current MM therapies. However, both antigens are also expressed on other normal tissues including hematopoietic lineages and immune effector cells, which may limit their long-term clinical use. B cell maturation antigen (BCMA), a transmembrane glycoprotein in the tumor necrosis factor receptor superfamily 17 (TNFRSF17), is expressed at significantly higher levels in all patient MM cells but not on other normal tissues except normal plasma cells. Importantly, it is an antigen targeted by chimeric antigen receptor (CAR) T-cells, which have already shown significant clinical activities in patients with RRMM who have undergone at least three prior treatments, including a proteasome inhibitor and an immunomodulatory agent. Moreover, the first anti-BCMA antibody-drug conjugate also has achieved significant clinical responses in patients who failed at least three prior lines of ...Continue Reading

References

Aug 30, 2002·Blood·Jaime O ClaudioA Keith Stewart
Nov 13, 2002·Annual Review of Immunology·Fabienne MackayJeffrey Browning
Jan 17, 2003·Mayo Clinic Proceedings·Robert A KylePhilip R Greipp
Mar 4, 2003·Nature Immunology·Jason D FontenotAlexander Y Rudensky
Jul 12, 2003·Blood·Angelo VaccaFranco Dammacco
Jul 17, 2003·The Journal of Clinical Investigation·Danielle T AveryStuart G Tangye
Jan 7, 2004·The Journal of Experimental Medicine·Brian P O'ConnorRandolph J Noelle
Sep 29, 2004·Journal of Molecular Biology·Heidi J A WallweberSarah G Hymowitz
Dec 1, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Toshiaki HayashiKenneth C Anderson
Jun 17, 2005·The New England Journal of Medicine·Paul G RichardsonUNKNOWN Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators
Aug 24, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Min YangAdrian T Ting
Jul 25, 2007·Nature Reviews. Cancer·Teru HideshimaKenneth C Anderson
Oct 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paola NeriNoopur Raje
Nov 21, 2007·Molecular Cancer Therapeutics·Maureen C RyanPaul J Carter
Mar 7, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Micah J BensonRandolph J Noelle
Mar 21, 2008·Nature Reviews. Cancer·Steven A RosenbergMark E Dudley
Jun 24, 2008·Nature·Arthur L ShafferLouis M Staudt
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Apr 18, 2009·Proceedings of the National Academy of Sciences of the United States of America·Joshua S KleinPamela J Bjorkman
Jun 11, 2009·Cancer Research·Patrick A Baeuerle, Carsten Reinhardt
Mar 18, 2011·The New England Journal of Medicine·Antonio Palumbo, Kenneth Anderson

❮ Previous
Next ❯

Citations

Jan 30, 2019·The Cancer Journal·Raphaël Szalat, Nikhil C Munshi
Jan 30, 2019·The Cancer Journal·Jill Corre, Hervé Avet-Loiseau
Feb 21, 2019·Expert Opinion on Pharmacotherapy·Jessica L DempseyHillard M Lazarus
Jul 7, 2019·Expert Opinion on Biological Therapy·Yu-Tzu Tai, Kenneth C Anderson
May 28, 2019·Frontiers in Immunology·Shivana M LightmanKelvin P Lee
Dec 24, 2019·Expert Review of Anticancer Therapy·Albert OriolAlicia Senin
Jan 7, 2020·Médecine sciences : M/S·Patrick Chames, Thierry Wurch
Mar 7, 2020·Cells·Cinnie Yentia SoekojoWee Joo Chng
Nov 23, 2018·Oncotarget·Brian A Walker, Gareth J Morgan
May 30, 2020·Scandinavian Journal of Immunology·Deming Feng, Jian Sun
Jun 27, 2020·Blood Advances·Poornima RamkumarMartin Kampmann
Aug 22, 2020·Expert Opinion on Investigational Drugs·Ying JiaoKongming Wu
Dec 14, 2018·International Journal of Molecular Sciences·Hanley N Abramson
Nov 30, 2019·Leukemia·Mattia D'Agostino, Noopur Raje
Dec 7, 2019·Biomarker Research·Delong Liu
Nov 30, 2019·Journal of Oncology·Hiroko Nishida, Taketo Yamada
May 12, 2020·Frontiers in Immunology·Chiara CaraccioChristian M Schürch
Jun 26, 2020·Frontiers in Immunology·Estefanía García-GuerreroJose Antonio Pérez-Simón
Aug 1, 2020·Journal of Clinical Medicine·Roberto TammaDomenico Ribatti
Jun 24, 2020·Leukemia·Nico GagelmannNicolaus Kröger
Oct 1, 2020·Journal of Clinical Medicine·María-Victoria MateosPaul G Richardson
Sep 19, 2020·Journal of Hematology & Oncology·Bo YuDelong Liu
May 2, 2019·Frontiers in Cell and Developmental Biology·Alfonso Serrano-Del ValleIsabel Marzo
Aug 6, 2019·Frontiers in Immunology·Marijke TimmersSébastien Anguille
Aug 28, 2020·Frontiers in Oncology·Jort J van der SchansTuna Mutis
Aug 10, 2020·Bone Marrow Transplantation·Binod DhakalMehdi Hamadani
Aug 13, 2020·Cancers·Ada Hang-Heng WongWee-Joo Chng
Sep 23, 2020·BMJ : British Medical Journal·Urvi A Shah, Sham Mailankody
Feb 21, 2019·Proceedings of the National Academy of Sciences of the United States of America·Zoë ShancerIra Pastan
Oct 18, 2019·Nature Reviews. Clinical Oncology·James T YurkovichLeroy Hood

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
xenograft

Clinical Trials Mentioned

NCT03486067
NCT03196414

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.